Synopsis
Synopsis
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Hydrochloride, Oxymetazoline
2. Oxymetazoline
1. 2315-02-8
2. Oxymetazoline Hcl
3. Ocuclear
4. Afrazine
5. Afrin Hydrochloride
6. Sch 9384
7. Rhofade
8. Oxymetazoline (hydrochloride)
9. Visine L.r.
10. Vicks Sinex
11. Nsc-757254
12. K89mj0s5vy
13. 6-tert-butyl-3-(4,5-dihydro-1h-imidazol-2-ylmethyl)-2,4-dimethylphenol;hydrochloride
14. Mls000038040
15. Chebi:7863
16. Agn-199201
17. Sch-9384
18. Smr000059324
19. 2-(4-t-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium Chloride
20. 2,6-dimethyl-2-(4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline Hydrochloride
21. 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol Monohydrochloride
22. 6-tert-butyl-3-(4,5-dihydro-1h-imidazol-2-ylmethyl)-2,4-dimethylphenol Hydrochloride
23. Phenol, 3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethyl-, Monohydrochloride
24. 2-(3-hydroxy-2,6-dimethyl-4-tert-butylbenzyl)-2-imidazoline
25. Lliadine
26. Nasivin
27. Nasivine
28. Neonabel
29. Nostrilla
30. Nafrine Hydrochloride
31. 4-way Nasal Spray
32. Duration Nasal Spray
33. Oxymetazoline Chloride
34. Lliadin Mini Paediatric
35. Sr-01000002705
36. Neo-synephrine 12 Hour
37. Neo-synephrine 12 Hour Ntz
38. Sinex
39. Anefrin Nasal
40. Duration 12 Hour Nasal Spray
41. Benzedrex Nasal Spray 12 Hour
42. Dristan Long Lasting Nasal Mist
43. Sudafed Om
44. Ocuclear (tn)
45. Prestwick_373
46. Einecs 219-015-0
47. St. Joseph Nasal Spray For Children
48. Mfcd00058147
49. Rhfade (tn)
50. Upneeq
51. Opera_id_32
52. 2-(3-hydroxy-2,6-dimethyl-4-t-butylbenzyl)-2-imidazoline Hydrochloride
53. Unii-k89mj0s5vy
54. 3-[(4,5-dihydro-
55. Schembl41247
56. Mls002222207
57. Spectrum1500453
58. Oxymetazoline Hydrochloride,(s)
59. Chembl1200791
60. Hy-b0427a
61. Dtxsid80177729
62. Oximetazoline Hydrochloride
63. Hms1568n09
64. Hms1920d18
65. Pharmakon1600-01500453
66. Tox21_500903
67. Ccg-40216
68. Nsc757254
69. 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol Hydrochloride
70. Akos000280887
71. Oxymetazoline Hydrochloride (jan/usp)
72. Phenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-, Hydrochloride
73. Ks-5222
74. Lp00903
75. Nsc 757254
76. Oxymetazoline Hydrochloride [mi]
77. Ncgc00094218-01
78. Ncgc00094218-02
79. Ncgc00094218-03
80. Ncgc00094218-04
81. Ncgc00094218-05
82. Ncgc00261588-01
83. Oxymetazoline Hydrochloride [jan]
84. 2315-02-8 (hcl)
85. Oxymetazoline Hydrochloride [usan]
86. Oxymetazoline Hydrochloride [mart.]
87. Oxymetazoline Hydrochloride [vandf]
88. 4-(2-boc-amino-pyridin-4-yl)-benzoicacid
89. Oxymetazoline Hydrochloride [who-dd]
90. Oxymetazoline Hydrochloride, >=99%, Solid
91. Eu-0100903
92. Ft-0673462
93. O0520
94. Oxymetazoline Hydrochloride [usan:usp:jan]
95. Sw196632-3
96. D01022
97. D91882
98. O 2378
99. Oxymetazoline Hydrochloride, Analytical Standard
100. Oxymetazoline Hydrochloride [orange Book]
101. 315o028
102. A910982
103. Oxymetazoline Hydrochloride [ep Monograph]
104. Oxymetazoline Hydrochloride [usp Impurity]
105. Oxymetazoline Hydrochloride [usp Monograph]
106. Kovanaze Component Oxymetazoline Hydrochloride
107. Sr-01000002705-2
108. Sr-01000002705-4
109. Sr-01000002705-7
110. W-107424
111. Q27107602
112. Oxymetazoline Hydrochloride Component Of Kovanaze
113. Sinex Vapospray Moisturizing 12-hour Decongestant Ultrafine Mist
114. 2,6-dimethyl-4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline Hydrochloride
115. 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium Chloride
116. 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol Hydrochloride
117. Oxymetazoline Hydrochloride, European Pharmacopoeia (ep) Reference Standard
118. 1h-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol Hydrochloride
119. 2-(3-hydroxy-2,6-dimethyl-4-tert-butylbenzyl)-2-imidazoline Hydrochloride
120. 2-(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-4,5-dihydro-1h-imidazol-1-ium Chloride
121. 6-(tert-butyl)-3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-2,4-dimethylphenol Hydrochloride
122. 6-tert-butyl-3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-2,4-dimethylphenol Hydrochloride
123. Oxymetazoline Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
124. Oxymetazoline Hydrochloride, United States Pharmacopeia (usp) Reference Standard
125. 3-[(4,5-dihydro-1h-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-phenol Hydrochloride
Molecular Weight | 296.83 g/mol |
---|---|
Molecular Formula | C16H25ClN2O |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 3 |
Exact Mass | 296.1655411 g/mol |
Monoisotopic Mass | 296.1655411 g/mol |
Topological Polar Surface Area | 44.6 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 345 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Nasal Decongestants
Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) (See all compounds classified as Nasal Decongestants.)
Sympathomimetics
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)
Adrenergic alpha-Agonists
Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Chynops Pharma is an ideal sourcing partner for high-quality APIs, advanced intermediates, speciality chemicals & excipients.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-02-15
Pay. Date : 2019-02-11
DMF Number : 8940
Submission : 1991-01-18
Status : Active
Type : II
NDC Package Code : 65724-4503
Start Marketing Date : 2010-03-02
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-09-18
Pay. Date : 2013-01-04
DMF Number : 22401
Submission : 2008-12-10
Status : Active
Type : II
Certificate Number : R1-CEP 2008-324 - Rev 03
Issue Date : 2018-05-18
Type : Chemical
Substance Number : 943
Status : Valid
Date of Issue : 2022-06-24
Valid Till : 2025-07-02
Written Confirmation Number : WC-0097
Address of the Firm :
NDC Package Code : 42419-005
Start Marketing Date : 2008-12-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4230
Submission : 1981-06-15
Status : Inactive
Type : II
Certificate Number : R1-CEP 2008-064 - Rev 02
Issue Date : 2021-01-15
Type : Chemical
Substance Number : 943
Status : Valid
Registration Number : 220MF10107
Registrant's Address : Karlstrasse 15, 32423, Minden, Federal Republic of Germany
Initial Date of Registration : 2008-04-11
Latest Date of Registration : --
NDC Package Code : 65724-4503
Start Marketing Date : 2010-03-02
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4290
Submission : 1981-10-08
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-09-18
Pay. Date : 2013-01-04
DMF Number : 22401
Submission : 2008-12-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4290
Submission : 1981-10-08
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-02-15
Pay. Date : 2019-02-11
DMF Number : 8940
Submission : 1991-01-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4230
Submission : 1981-06-15
Status : Inactive
Type : II
Certificate Number : R1-CEP 2008-324 - Rev 03
Status : Valid
Issue Date : 2018-05-18
Type : Chemical
Substance Number : 943
Certificate Number : R1-CEP 2008-064 - Rev 02
Status : Valid
Issue Date : 2021-01-15
Type : Chemical
Substance Number : 943
Registration Number : 220MF10107
Registrant's Address : Karlstrasse 15, 32423, Minden, Federal Republic of Germany
Initial Date of Registration : 2008-04-11
Latest Date of Registration : 2024-02-21
Date of Issue : 2022-06-24
Valid Till : 2025-07-02
Written Confirmation Number : WC-0097
Address of the Firm : Block No. 251/P, 252/P, 253 to 255, 256/P,258/P, 276/P, 277/P, 278/P, 279 To 282...
NDC Package Code : 42419-005
Start Marketing Date : 2008-12-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71052-482
Start Marketing Date : 2021-11-15
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62991-3201
Start Marketing Date : 2024-02-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51927-3205
Start Marketing Date : 2013-06-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 69056-005
Start Marketing Date : 2024-08-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65724-4503
Start Marketing Date : 2010-03-02
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49452-4954
Start Marketing Date : 2000-07-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : Pharm-Rx has earned an outstanding reputation since its establishment in 1991, serving as a reputable importer and distributor of active ingredients to the pharmaceutical, nutritio...
Chynops Pharma is an ideal sourcing partner for high-quality APIs, advanced intermediates, speciality chemicals & excipients.
About the Company : Chynops Pharma, a company certified with ISO 9001:2015, is situated in Ahmedabad, India. We specialize in exporting, supplying, and trading a wide range of products, including APIs...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : Nortec Química stands as the largest manufacturer of Active Pharmaceutical Ingredients (IFAs) in Latin America, embarking on its mission to ensure the availability of quality medi...
About the Company : CTX is one of the youngest and fastest-growing Indian API and Intermediate manufacturing companies doing business in over 70 countries. In these five years, all my thoughts and act...
About the Company : Globela has been at the forefront of innovation for nearly seventy years. From humble beginnings in 2006 as a small pharmaceutical company, Globela’s current portfolio of vertica...
About the Company : As an internationally renowned outsourcing partner, we offer products and tailor-made service packages that are seamlessly embedded in the value chain of our customers. Our pharmac...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharoptosis.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: LEV102
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis
Details : LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharo...
Brand Name : LEV102
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2023
Details:
Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trials in adults.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Dermatology Brand Name: Rhofade
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Sato Yakuhin Kogyo Co., Ltd
Deal Size: $7.5 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement December 21, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Sato Yakuhin Kogyo Co., Ltd
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...
Brand Name : Rhofade
Molecule Type : Small molecule
Upfront Cash : $5.0 million
December 21, 2022
Details:
Afrin® (oxymetazoline hydrochloride) provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old unblocks a stuffy nose fast.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Afrin
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Afrin® WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays – Because One Sick...
Details : Afrin® (oxymetazoline hydrochloride) provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old unblocks a stuffy nose fast.
Brand Name : Afrin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2022
Details:
As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Upneeq
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: RVL Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 30, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : RVL Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.
Details : As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 30, 2022
Details:
The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Upneeq
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Athyrium Capital
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 04, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Athyrium Capital
Deal Size : $24.0 million
Deal Type : Private Placement
RVL Pharmaceuticals Plc Announces Insider and Athyrium-Led Financing
Details : The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 04, 2022
Details:
Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Dermatology Brand Name: Rhofade
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Novan
Deal Size: $51.0 million Upfront Cash: $27.5 million
Deal Type: Acquisition March 11, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Novan
Deal Size : $51.0 million
Deal Type : Acquisition
Novan Acquires EPI Health, a Specialty Dermatology Company
Details : Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.
Brand Name : Rhofade
Molecule Type : Small molecule
Upfront Cash : $27.5 million
March 11, 2022
Details:
The financing provides the Company with additional cash to support the commercialization of Upneeq. As a first-in-class treatment for acquired ptosis, Upneeq offers patients and clinicians a convenient non-surgical therapeutic option.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Upneeq
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Athyrium Capital Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 07, 2021
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Athyrium Capital Management
Deal Size : Undisclosed
Deal Type : Financing
Details : The financing provides the Company with additional cash to support the commercialization of Upneeq. As a first-in-class treatment for acquired ptosis, Upneeq offers patients and clinicians a convenient non-surgical therapeutic option.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 07, 2021
Details:
Osmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ (Oxymetazoline Hydrochloride).
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Upneeq
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Alora Pharmaceuticals
Deal Size: $170.0 million Upfront Cash: $110.0 million
Deal Type: Divestment June 25, 2021
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Alora Pharmaceuticals
Deal Size : $170.0 million
Deal Type : Divestment
Details : Osmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ (Oxymetazoline Hydrochloride).
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : $110.0 million
June 25, 2021
Details:
Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Upneeq
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2020
Details:
Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Upneeq
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: RVL Pharmaceuticals
Deal Size: $89.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement July 28, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : RVL Pharmaceuticals
Deal Size : $89.0 million
Deal Type : Licensing Agreement
Details : Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : $25.0 million
July 28, 2020
RLD : No
TE Code :
Brand Name : OCUCLEAR
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 0.025%
Approval Date : 1986-05-30
Application Number : 18471
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : VISINE L.R.
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 0.025%
Approval Date : 1989-03-31
Application Number : 19407
RX/OTC/DISCN : OTC
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : RHOFADE
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%
Approval Date : 2017-01-18
Application Number : 208552
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : UPNEEQ
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 0.1%
Approval Date : 2020-07-08
Application Number : 212520
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE
Brand Name : KOVANAZE
Dosage Form : SPRAY, METERED;NASAL
Dosage Strength : 0.1MG/SPRAY;6MG/SPRAY
Approval Date : 2016-06-29
Application Number : 208032
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code :
Brand Name : OXYMETAZOLINE HYDROCHLORIDE
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%
Approval Date : 2021-10-04
Application Number : 213584
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD :
TE Code :
Brand Name : OXYMETAZOLINE
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%
Approval Date :
Application Number : 211812
RX/OTC/DISCN :
RLD :
TE Code :
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
Oxymetazoline impurity A
CAS Number : n/a
Quantity Per Vial : 15 mg
Sale Unit : 1
Order Code : Y0001044
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C
Oxymetazoline hydrochloride
CAS Number : 2315-02-8
Quantity Per Vial : 80 mg
Sale Unit : 1
Order Code : O0290000
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?